A clinical armamentarium of marine-derived anti-cancer compounds

Anti-Cancer Drugs

Volumn 13, Issue SUPPL. 1, 2002, Pages

  Jimeno, José M ^a  

^a PHARMAMAR S A   (Spain)

Author keywords

Anti cancer; Aplidine; Ecteinascidin 743; ES 285; Kahalalide F; Marine

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DEHYDRODIDEMNIN B; ES 285; KAHALALIDE F; TRABECTEDIN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; CYCLOPEPTIDE; DEPSIPEPTIDE; ISOQUINOLINE DERIVATIVE; PEPTIDE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BIOTECHNOLOGY; CONFERENCE PAPER; DRUG ISOLATION; DRUG POTENCY; ENZYME ACTIVITY; MARINE ENVIRONMENT; MOLLUSC; PRIORITY JOURNAL; ANIMAL; BIOLOGY; DRUG SCREENING; HUMAN; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; DIOXOLES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; ISOQUINOLINES; MARINE BIOLOGY; MOLLUSCA; PEPTIDES; PEPTIDES, CYCLIC; ANIMALS; DEPSIPEPTIDES; HUMANS; TETRAHYDROISOQUINOLINES;

EID: 0036273081     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Natural products in drug discovery and development
2. Discovery and development of antineoplastic agents from natural sources
3. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
4. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata
5. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
6. Ecteinascidin-743: A minor groove alkylator that bends DNA towards the major groove
7. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
8. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
9. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
10. ET-743: A marine natural product with high antitumor activity in human tumour xenograft models
11. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
12. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of Phase II and pharmacokinetic studies in the USA
13. Ecteinascidin-743 given as a 24-hour intravenous continuous infusion every 3 weeks: Results of a Phase II trial in patients with pretreated soft tissue sarcomas
14. ET-743 is an active drug in adult soft-tissue sarcoma: A STBSG-EORTC Phase II trial
15. Preliminary results of Phase II study of ecteinascidin-743 with the 24-hour continuous infusion Q3 weeks schedule in pretreated advanced/metastatic breast cancer patients
16. Ecteinascidin-743 in ovarian cancer: Activity in xenografts and preliminary results of an ongoing study in patients failing platinum-taxanes
17. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer
18. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
19. Mechanism of antileukemic activity of aplidin
20. Preclinical characterization of aplidin (APD), a new marine anticancer depsipeptide (MADEP)
21. In vitro activity of aplidin, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells
22. Schedule dependency of Aplidin, a marine depsipeptide with antitumor activity
23. Phase I trials with Aplidine, a new marine-derived anticancer compound
24. In vitro sensitivity to aplidine in normal bone marrow and blood in leukemic samples from children
25. The antitumoral compound kahalalide F acts on cell lysosomes
26. Preclinical development of kahalalide F, a new marine compound selected for clinical studies
27. Investigation of the effects of kahalalide F (PM92102) against human tumor specimens taken directly from patients
28. Phase I and pharmacokinetic study of kahalalide-F in patients with advanced androgen-refractory prostate cancer
29. Farnesyltransferase inhibitors: Antineoplastic mechanisms and clinical prospects
30. ES-285, a marine natural product with activity against solid tumours